All In Biotech

Drug Trial Radar · NCT06846099

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Indications of RP903

A Phase I/Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Indications of Pl3Kα-Selective Inhibitor RP903 (JS105) in Subjects With Advanced Malignancies

Last checked: Nov 19, 2026Latest source record: Dec 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

69

Actual

Start

Dec 7, 2022

Primary completion

May 30, 2025

Study completion May 30, 2025

Sponsor

Sponsor type
Industry
First posted
Feb 25, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open phase I/Ib clinical study to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and initial efficacy of RP903 in patients with advanced malignancies who have failed standard treatment or have no standard treatment options. The study was divided into two parts: dose escalation and dose extension (Phase Ia) and clinical extension (Phase Ib).

Conditions

  • Ovarian Cancer
  • Cervical Cancer
  • Endometrial Cancer
  • Breast Cancer
  • Solid Tumor Cancer

Interventions

  • RP903Drug

    Ia:RP903 50mg, 100mg, 200mg, 300mg,350mg,or other dose, po qd for each 28-day cycle; Ib: RP903,RP2D,po qd for each 28-day cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ia:dose-limiting toxicity(DLTs)Time frame: 28 days
  2. Ia:Adverse EventsTime frame: 2 years
  3. Ia: serious adverse eventsTime frame: 2 years
  4. Ia: Abnormal changes in Laboratory test and other abnormalitiesTime frame: 2 years
  5. Ia: MTDTime frame: 2 years
  6. Ia: MADTime frame: 2 years
  7. Ia:RP2DTime frame: 2 years
  8. Ib:objective response rate(ORR);Time frame: 2 years
  9. Ib:AETime frame: 2 years
  10. Ib:SAETime frame: 2 years

Locations

23 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Cancer Hospital

    Beijing, China

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, China

  • Jilin Cancer Hospital

    Changchun, China

  • Jilin University First Hospital

    Changchun, China

  • Sichuan Cancer Hospital

    Chengdu, China

  • Chongqing University Cancer Hospital

    Chongqing, China

  • Fujian Cancer Hospital

    Fuzhou, China

  • Fujian Medical University Union Hospital

    Fuzhou, China

  • Sir Run Run Shaw Hospital

    Hangzhou, China

  • Zhejiang Cancer Hospital

    Hangzhou, China

  • Harbin Medical University Cancer Hospital

    Harbin, China

  • Shandong Cancer Hospital & Institute

    Jinan, China

  • Affiliated Hospital of Jining Medical College

    Jining, China

  • Linyi Cancer Hospital

    Linyi, China

  • The First Affiliated Hospital of Henan University of Science and Technology

    Luoyang, China

  • Guangxi Medical University Cancer Hospital

    Nanning, China

  • The Affiliated Hospital of Qingdao University

    Qingdao, China

  • Affiliated Cancer Hospital of Fudan University

    Shanghai, China

  • Liaoning Cancer Hospital&Institute

    Shenyang, China

  • Suining Central Hospital

    Suining, China

  • Hubei Cancer Hospital

    Wuhan, China

  • Ceneral Hosipital of Ningxia Medical University

    Yinchuan, China

  • Henan Cancer Hospital

    Zhengzhou, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.